RYGB and the Gastric Adipose Axis

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if interruption in gastric-adipose tissue axis signaling contributes to early improvements in oxidative stress, insulin sensitivity, and inflammation, and to determine if interruption of the stomach in RYGB results in reduction of plasma acylated ghrelin (AG) and in an altered acylated ghrelin:unacylated ghrelin (AG:UAG) ratio which may contribute to decreased oxidative stress and improved insulin sensitivity.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Criteria

PROTOCOL I

Inclusion Criteria:

• Age 18-65 years

• BMI ≥ 35 kg/m^2

• Scheduled for bariatric surgery

• Considering bariatric surgery

• Waiting for insurance approval for bariatric surgery

• Currently not considering bariatric surgery, but otherwise eligible

• Enrollment in medical weight loss program

Exclusion Criteria:

• Smoking >7 cigarettes per day

• Precious malabsorptive or restrictive intestinal surgery

• Pregnant or breastfeeding

• Recent history of neoplasia (5- Malabsorptive syndromes

• Inflammatory intestinal disease

• Established organ disfunction

• Allergy to acetaminophen